

# Masaki Kanazu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9290683/publications.pdf>

Version: 2024-02-01

12  
papers

335  
citations

1307594

7  
h-index

1199594

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

662  
citing authors

#	ARTICLE	IF	CITATIONS
1	Histologic transformation of epidermal growth factor receptor-mutated lung cancer. <i>European Journal of Cancer</i> , 2022, 166, 41-50.	2.8	10
2	Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. <i>Thoracic Cancer</i> , 2022, 13, 2450-2458.	1.9	4
3	Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study. <i>Thoracic Cancer</i> , 2021, 12, 90-96.	1.9	5
4	EGFR mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib. <i>Thoracic Cancer</i> , 2021, 12, 1441-1444.	1.9	3
5	Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report. <i>Thoracic Cancer</i> , 2021, 12, 1935-1939.	1.9	3
6	Treatment Rationale and Design of a Phase III Study of Afatinib or Chemotherapy in Patients with Non-small-cell Lung Cancer Harboring Sensitizing Uncommon Epidermal Growth Factor Receptor Mutations (ACHILLES/TORG1834). <i>Clinical Lung Cancer</i> , 2020, 21, e592-e596.	2.6	5
7	Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: A retrospective cohort study. <i>Thoracic Cancer</i> , 2020, 11, 3317-3325.	1.9	20
8	Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. <i>PLoS ONE</i> , 2019, 14, e0220570.	2.5	20
9	Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series. <i>Thoracic Cancer</i> , 2018, 9, 1782-1787.	1.9	23
10	Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. <i>JCI Insight</i> , 2018, 3, .	5.0	156
11	Case series of pleomorphic carcinomas of the lung treated with nivolumab. <i>Thoracic Cancer</i> , 2017, 8, 724-728.	1.9	39
12	Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report. <i>Lung Cancer</i> , 2017, 109, 42-44.	2.0	47